Peptide directoryBrain, hypothalamus & pituitary

Vasopressin

The water hormone, which concentrates urine, tightens vessels and shapes bonding.

Related medicinesDesmopressinTerlipressinVasopressinTolvaptan

Where it comes from

Made in
Large neurons of the supraoptic and paraventricular nuclei, whose axons end in the posterior pituitary
Sent out by
A rise in blood osmolality of one percent, a fall in blood volume or pressure, nausea, pain and stress
Acts on
  • Collecting ducts of the kidney (water channels)
  • Arterioles
  • Pituitary corticotrophs (ACTH)
  • Liver (glycogen)
  • Brain circuits of social behaviour

What it does

  • Puts aquaporin-2 water channels into the collecting duct so water is kept and urine concentrates
  • Constricts vessels in shock, when it is released in huge amounts
  • Governs pair bonding and aggression in voles, and social behaviour in people in a subtler way

In medicine

  • Desmopressin, a V2-selective analogue, treats arginine vasopressin deficiency (central diabetes insipidus), bedwetting, and bleeding in haemophilia A and von Willebrand disease
  • Vasopressin infusion is a second-line pressor in septic shock; terlipressin treats hepatorenal syndrome and variceal bleeding 1
  • Tolvaptan, a V2 blocker, treats low sodium from inappropriate vasopressin and slows polycystic kidney disease 2

Beyond the body’s own use

  • In 778 patients with septic shock, adding vasopressin to noradrenaline did not lower mortality overall, which is why it stays a second-line rather than a first-line pressor 1
  • Tolvaptan slowed cyst growth and the loss of kidney function over three years in 1,445 patients with polycystic kidney disease, at the cost of thirst and raised liver enzymes 2
  • Intranasal vasopressin improved social abilities against placebo in a pilot trial of 30 children with autism, a result that has not been repeated at scale 3
  • Blocking the same system was tried too: balovaptan, a V1a blocker, improved adaptive behaviour in a phase 2 trial in men with autism, and the later trials did not confirm it 4

Sources

  1. Russell et al., Vasopressin versus norepinephrine infusion in patients with septic shock, New England Journal of Medicine 2008
  2. Torres et al., Tolvaptan in patients with autosomal dominant polycystic kidney disease, New England Journal of Medicine 2012
  3. Parker et al., Intranasal vasopressin improves social deficits in children with autism, Science Translational Medicine 2019
  4. Bolognani et al., A vasopressin V1a receptor antagonist in men with autism spectrum disorder, Science Translational Medicine 2019

This card describes what a medicine is for and what the evidence says; it recommends nothing. Talk to your clinician about anything you read here.